Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
PARP inhibitors (PARPis) have clinical efficacy in BRCA-deficient cancers, but not BRCA-intact tumors, including glioblastoma (GBM). We show that MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repressio...
Main Authors: | Stanciu, Monica, Lees, Jacqueline |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC
2020
|
Online Access: | https://hdl.handle.net/1721.1/125202 |
Similar Items
-
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
by: Kamila Burdova, et al.
Published: (2019-10-01) -
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
by: Schoonen, P, et al.
Published: (2017) -
Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium
by: Kolb, A, et al.
Published: (2017) -
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
by: Shiro Takamatsu, et al.
Published: (2024-02-01) -
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
by: Álvaro Lahiguera, et al.
Published: (2020-06-01)